KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Debt Repayments (2020 - 2025)

Recursion Pharmaceuticals' Long-Term Debt Repayments history spans 6 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments rose 3.14% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $8.4 million, up 89.75%, while the annual FY2025 figure was $8.4 million, 89.75% up from the prior year.
  • Long-Term Debt Repayments reached $2.2 million in Q4 2025 per RXRX's latest filing, up from $2.1 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $12.7 million in Q3 2021 to a low of $20000.0 in Q1 2021.
  • Average Long-Term Debt Repayments over 5 years is $1.3 million, with a median of $25000.0 recorded in 2023.
  • Peak YoY movement for Long-Term Debt Repayments: skyrocketed 63585.0% in 2021, then plummeted 99.82% in 2022.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $21000.0 in 2021, then increased by 9.52% to $23000.0 in 2022, then surged by 2917.39% to $694000.0 in 2023, then surged by 202.74% to $2.1 million in 2024, then grew by 3.14% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Long-Term Debt Repayments are $2.2 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025).